MedTrace Logo

Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

NCT03747497 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2022-11-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether contezolid acefosamil is as safe and effective as linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections

Conditions

  • Skin Diseases, Bacterial
  • Gram-Positive Bacterial Infections

Interventions

DRUG

contezolid acefosamil

IV and oral contezolid acefosamil given twice a day for 10 to 14 days

DRUG

linezolid 600 mg

IV and oral linezolid given twice a day for 10 to 14 days

Sponsors & Collaborators

  • MicuRx

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-15
Primary Completion
2019-03-26
Completion
2019-03-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03747497 on ClinicalTrials.gov